CN1812971A - 培哚普利特丁胺的新晶形 - Google Patents

培哚普利特丁胺的新晶形 Download PDF

Info

Publication number
CN1812971A
CN1812971A CNA2004800178672A CN200480017867A CN1812971A CN 1812971 A CN1812971 A CN 1812971A CN A2004800178672 A CNA2004800178672 A CN A2004800178672A CN 200480017867 A CN200480017867 A CN 200480017867A CN 1812971 A CN1812971 A CN 1812971A
Authority
CN
China
Prior art keywords
crystalline form
perindopril
water
methyl ether
butyl methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2004800178672A
Other languages
English (en)
Other versions
CN100395235C (zh
Inventor
C·施特雷斯勒
V·勒列科
R·费斯勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Servier SAS filed Critical Laboratoires Servier SAS
Publication of CN1812971A publication Critical patent/CN1812971A/zh
Application granted granted Critical
Publication of CN100395235C publication Critical patent/CN100395235C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明公开了培哚普利特丁胺的两种新晶形，即δ和ε晶形。这些晶形适合作为用于治疗心血管疾病、尤其是高血压和心力衰竭的药物的治疗活性物质。ε晶形是通过使培哚普利特丁胺在30至45℃下、优选在34至45℃下从含有1.5至2.5％(v/v)水的MTBE中结晶获得的；所述结晶有利地在搅拌下进行。如果除去水，有利地通过共沸蒸馏除去，优选在35至37℃下进行，并且在30至45℃下、优选在35至37℃下继续搅拌至少15小时，ε晶形转化为δ晶形。δ晶形也可以通过在用δ晶形引入晶种的同时将α或β晶形的培哚普利特丁胺于33至38℃下在含有0.9至1.4％v/v水的叔丁基甲基醚中搅拌来获得。ε晶形也可以通过在用ε晶形引入晶种的同时将α或β晶形的培哚普利特丁胺于28至35℃下在含有0.9至1.4％(v/v)水的叔丁基甲基醚中搅拌来获得；或者通过将α或β晶形于35至38℃下在含有1.5至2.0％(v/v)水的叔丁基甲基醚中搅拌来获得。

Description

培哚普利特丁胺的新晶形
本发明涉及培哚普利特丁胺的两种新晶形。
培哚普利((2S，3aS，7aS)-1-[2-(1-乙氧基羰基-(S)-丁基氨基)-(S)-丙酰基]-八氢吲哚-2-甲酸)具有以下式(I)的结构：
Figure A20048001786700051
培哚普利特丁胺是培哚普利的叔丁基胺盐。
培哚普利是ACE抑制剂(ACE＝血管紧张素转化酶)，用于治疗心血管疾病，尤其是治疗高血压和心力衰竭。
合成培哚普利的方法在EP 49 658、US 4,508,729、EP 308 341和US4,914,214中有记载，在EP 1 256 590和WO 01/58868中也有记载。
在WO 01/87835、WO 01/87836和WO 01/83439中记载了使培哚普利特丁胺从乙酸乙酯中(WO 01/87835)、从二氯甲烷或乙酸乙酯(WO01/87836)和从氯仿中(WO 01/83439)结晶的方法以及在那些方法中获得的α(WO 01/87835)、β(WO 01/87836)和γ(WO 01/83439)晶形。
现已发现通过使任一晶形的培哚普利特丁胺从含有0.9至2.5％v/v水的叔丁基甲基醚中结晶或者通过在含有0.9至2.5％v/v水的叔丁基甲基醚中对培哚普利特丁胺的α或β晶形进行转化，可能获得两种其它的晶形，即δ和ε晶形，这取决于精确的条件。这些新的δ和ε晶形通过以下的X-射线衍射数据进行表征(参见下面的表1和表2)：
表1：培哚普利特丁胺δ晶形的X-射线衍射数据(由通过CuKα照射得到的粉末图谱获得相对强度)
  2θ角(°)   晶格间距d(_)   相对强度I/Imax(％)
  5.27   16.79   2
  8.93   9.93   100
  9.75   9.10   32
  10.65   8.34   10
  14.63   6.10   25
  14.97   5.97   39
  15.27   5.85   48
  15.95   5.61   53
  17.27   5.19   18
  17.87   5.02   15
  18.63   4.83   13
  19.99   4.51   29
  20.37   4.43   26
  21.31   4.24   57
  21.83   4.15   37
  22.49   4.03   26
  23.15   3.92   19
  23.65   3.84   29
  23.99   3.79   16
  24.71   3.69   15
  25.33   3.60   15
  25.75   3.55   15
  26.43   3.46   21
  26.77   3.42   18
  28.19   3.26   24
注：众所周知强度可能由于结构影响而变化。
表2：培哚普利特丁胺ε晶形的X-射线衍射数据(由通过CuKα照射得到的粉末图谱获得相对强度)
  2θ角(°)   晶格间距d(_)   相对强度I/Imax(％)
  5.28   16.75   2
  8.43   10.52   22
  8.87   10.00   100
  9.45   9.39   92
  10.01   8.87   20
  13.58   6.57   6
  14.21   6.28   14
  14.79   6.04   61
  15.31   5.84   53
  15.84   5.65   49
  16.43   5.45   13
  16.84   5.32   13
  17.65   5.09   18
  18.65   4.82   11
  19.87   4.54   29
  21.21   4.26   49
  21.79   4.15   55
  22.79   3.98   27
  23.52   3.86   30
  24.25   3.75   25
  25.83   3.54   23
  26.55   3.45   25
  27.25   3.37   15
  28.11   3.27   27
注：众所周知强度可能由于结构影响而变化。
根据本发明，ε晶形是通过使任一晶形的培哚普利特丁胺在30至45℃下、优选在34至45℃下从含有1.5至2.5％v/v水的叔丁基甲基醚(MTBE)中结晶获得的；所述结晶有利地在搅拌下进行。如果之后除去水，有利地通过共沸蒸馏除去，优选在35至37℃下进行，然后在30至45℃下、优选在35至37℃下继续搅拌至少15小时，则ε晶形转化为δ晶形。
另外，通过在33至38℃下、优选在35至37℃下在含有0.9至1.4％v/v水、优选含有1.0至1.1％v/v水的叔丁基甲基醚(MTBE)中进行搅拌并用δ晶形引入晶种可将已知的培哚普利特丁胺的α和β晶形转化为δ晶形。
在含有0.9至1.4％v/v水、优选含有1.0至1.1％v/v水的叔丁基甲基醚(MTBE)中，通过用ε晶形引入晶种可以在28至35℃下、优选在31至33℃下将已知的α和β晶形转化为ε晶形。
不引入晶种也可以进行这些转化，但是在边缘区域当然无法确定地预测获得的是δ晶形、ε晶形还是这些晶形的混合物。
α和β晶形向ε晶形的转化也可以于35至38℃下在含有1.5至2.0％v/v水的叔丁基甲基醚(MTBE)中进行。
培哚普利特丁胺的δ和ε晶形均是新晶形并且是本发明所涉及的内容。
根据本发明，它们可以用作治疗活性物质，并且可与可药用的载体材料一起被加工成药物。所述药物则可以用于治疗心血管疾病，尤其是治疗高血压和心力衰竭。
用于制备药物的可药用载体材料是通常已知的，并且对本领域技术人员而言是熟悉的。
由于药学活性物质的不同形式例如新的结晶形式通常表现出不同的生物利用度、溶解性和溶出速率，所以它们可能对相关的病人非常有利，因为它们使得降低剂量或延长给药间隔并最终减少用药花费成为可能。
以下实施例用于对本发明进行举例说明，但不以任何方式限制本发明的范围及其应用：
在Philips ADP1700粉末衍射仪上使用Kα1＝0.15406nm和Kα2＝0.15444的Cu照射和40kV的电压测定X-射线衍射谱。
实施例1：培哚普利特丁胺的ε晶形
将5.00g培哚普利特丁胺混悬在50ml MTBE中，加入0.95ml水。在搅拌下将所得混悬液加热至48℃，形成澄清的溶液。在搅拌下将该溶液冷却至41℃。在该温度下引入晶种，之后开始结晶。在40至41℃下搅拌30分钟，然后在1小时期间将混合物冷却至34℃。将所得的沉淀物滤出，用10ml MTBE洗涤。干燥后，获得1.85gε晶形的培哚普利特丁胺。
实施例2：培哚普利特丁胺的δ晶形
将11.09g培哚普利特丁胺混悬在130ml MTBE中，加入2ml水。在搅拌下将所得混悬液加热至51℃，形成澄清的溶液。在搅拌下于120分钟期间将溶液冷却至35℃。在44℃下引入晶种，之后开始结晶。在35至37℃下于45分钟期间减压蒸馏除去50ml MTBE。同时也通过共沸除去了水。然后再加入50ml MTBE并在35至37℃下于60分钟期间再次减压蒸馏除去50ml MTBE。在35至37℃下继续搅拌15小时，然后将所得的沉淀物滤出，用10ml MTBE洗涤。干燥后，获得8.42gδ晶形的培哚普利特丁胺。
实施例3：α晶形向δ晶形的转化
将8.50gα晶形的培哚普利特丁胺混悬在85ml MTBE中，在搅拌下将该混悬液加热至35至37℃。向其中加入0.85ml水，随后加入0.17gδ晶形的晶种。将所得混悬液在35至37℃下搅拌23小时，然后将沉淀物滤出。干燥后，获得7.00gδ晶形。
实施例4：α晶形向ε晶形的转化
将21.66gα晶形的培哚普利特丁胺混悬在216ml MTBE中，在搅拌下将该混悬液加热至33至35℃。向其中加入2.16ml水，将混悬液在33至35℃下搅拌14小时。将沉淀物滤出并干燥后，获得18.68gε晶形。
实施例5：β晶形向δ晶形的转化
将4.00gβ晶形的培哚普利特丁胺混悬在40ml MTBE中，加入0.36ml水。将所得混悬液加热至35至37℃，在35至37℃下搅拌20小时。将沉淀物滤出并干燥后，获得δ晶形。
实施例6：α晶形向ε晶形的转化
将7.55gα晶形的培哚普利特丁胺混悬在75ml MTBE中，在搅拌下将该混悬液加热至35至37℃。向其中加入1.32ml水，将所得混悬液在35至37℃下搅拌20小时。将沉淀物滤出并干燥后，获得2.31gε晶形。

Claims (8)

1.培哚普利特丁胺的δ晶形，其用以下X-射线衍射数据(用CuKα照射在粉末衍射仪上测定)表征：   2θ角(°)   晶格间距d(_)   相对强度I/Imax(％)   5.27   16.79   2   8.93   9.93   100   9.75   9.10   32   10.65   8.34   10   14.63   6.10   25   14.97   5.97   39   15.27   5.85   48   15.95   5.61   53   17.27   5.19   18   17.87   5.02   15   18.63   4.83   13   19.99   4.51   29   20.37   4.43   26   21.31   4.24   57   21.83   4.15   37   22.49   4.03   26   23.15   3.92   19   23.65   3.84   29   23.99   3.79   16   24.71   3.69   15   25.33   3.60   15   25.75   3.55   15   26.43   3.46   21   26.77   3.42   18   28.19   3.26   24
2.培哚普利特丁胺的ε晶形，其用以下X-射线衍射数据(用CuKα照射在粉末衍射仪上测定)表征：   2θ角(°)   晶格间距d(_)   相对强度I/Imax(％)   5.28   16.75   2   8.43   10.52   22   8.87   10.00   100   9.45   9.39   92   10.01   8.87   20   13.58   6.57   6   14.21   6.28   14   14.79   6.04   61   15.31   5.84   53   15.84   5.65   49   16.43   5.45   13   16.84   5.32   13   17.65   5.09   18   18.65   4.82   11   19.87   4.54   29   21.21   4.26   49   21.79   4.15   55   22.79   3.98   27   23.52   3.86   30   24.25   3.75   25   25.83   3.54   23   26.55   3.45   25   27.25   3.37   15   28.11   3.27   27
3.用作治疗活性物质的权利要求1或2的培哚普利特丁胺的晶形。
4.含有权利要求1或2的培哚普利特丁胺的晶形的药物。
5.权利要求1或2的培哚普利特丁胺的晶形在治疗心血管疾病中和在制备相应药物中的用途。
6.权利要求5的用途，其中所述的心血管疾病是高血压和心力衰竭。
7.制备权利要求1的δ晶形的培哚普利特丁胺的方法，其特征在于：
a)使任一晶形的培哚普利特丁胺在30至45℃下从含有1.5至2.5％(v/v)水的叔丁基甲基醚中重结晶，除去水后将所得沉淀物在30至45℃下搅拌至少15小时；或者
b)将α或β晶形的培哚普利特丁胺于33至38℃下在含有0.9至1.4％(v/v)水的叔丁基甲基醚中进行搅拌，同时用δ晶形引入晶种。
8.制备权利要求2的ε晶形的培哚普利特丁胺的方法，其特征在于：
a)使任一晶形的培哚普利特丁胺在30至45℃下从含有1.5至2.5％(v/v)水的叔丁基甲基醚中重结晶；或者
b)将α或β晶形的培哚普利特丁胺于28至35℃下在含有0.9至1.4％(v/v)水的叔丁基甲基醚中进行搅拌，同时用ε晶形引入晶种；或者
c)将α或β晶形的培哚普利特丁胺于35至38℃下在含有1.5至2.0％(v/v)水的叔丁基甲基醚中进行搅拌。
CNB2004800178672A 2003-06-24 2004-06-18 培哚普利特丁胺的新晶形 Expired - Fee Related CN100395235C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH11092003 2003-06-24
CH1109/03 2003-06-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2008100912488A Division CN101333181A (zh) 2003-06-24 2004-06-18 培哚普利特丁胺的新晶形

Publications (2)

Publication Number Publication Date
CN1812971A true CN1812971A (zh) 2006-08-02
CN100395235C CN100395235C (zh) 2008-06-18

Family

ID=33520350

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB2004800178672A Expired - Fee Related CN100395235C (zh) 2003-06-24 2004-06-18 培哚普利特丁胺的新晶形
CNA2008100912488A Pending CN101333181A (zh) 2003-06-24 2004-06-18 培哚普利特丁胺的新晶形

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2008100912488A Pending CN101333181A (zh) 2003-06-24 2004-06-18 培哚普利特丁胺的新晶形

Country Status (22)

Country Link
US (2) US7705046B2 (zh)
EP (1) EP1636185B1 (zh)
JP (1) JP2007507418A (zh)
KR (1) KR20060035636A (zh)
CN (2) CN100395235C (zh)
AT (1) ATE540924T1 (zh)
AU (1) AU2004249345B8 (zh)
BR (1) BRPI0411966A (zh)
CA (1) CA2530550C (zh)
CY (1) CY1112597T1 (zh)
DK (1) DK1636185T3 (zh)
EA (1) EA008603B1 (zh)
ES (1) ES2382171T3 (zh)
HK (1) HK1093984A1 (zh)
MX (1) MXPA05013811A (zh)
NO (1) NO333128B1 (zh)
NZ (1) NZ544160A (zh)
PL (1) PL1636185T3 (zh)
PT (1) PT1636185E (zh)
SI (1) SI1636185T1 (zh)
WO (1) WO2004113293A1 (zh)
ZA (1) ZA200600655B (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG125976A1 (en) * 2005-03-11 2006-10-30 Servier Lab New gama crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it
SG125975A1 (en) * 2005-03-11 2006-10-30 Servier Lab New alpha crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it
WO2007017894A2 (en) * 2005-05-05 2007-02-15 Arch Pharmalabs Limited PREPARATION OF NOVEL CRYSTALLINE η(ETA) FORM OF PERINDOPRIL ERBUMINE
WO2007017893A2 (en) * 2005-05-05 2007-02-15 Arch Pharmalabs Limited Preparation of novel crystalline form of perindopril erbumine monohydrate
AU2006281681A1 (en) * 2005-08-12 2007-02-22 Sandoz Ag New crystalline form of perindopril erbumine
MX2008002064A (es) * 2005-08-12 2008-04-17 Lek Pharmaceuticals Un proceso para la preparacion de perindopril-erbumina.
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
WO2007092758A2 (en) * 2006-02-03 2007-08-16 Dr. Reddy's Laboratories Ltd. Crystalline forms of perindopril erbumine
EA200600630A1 (ru) * 2006-04-20 2007-02-27 ИСМАГИЛОВ, Искандар Халиуллович ζ-ЗЕТА ФОРМА ПЕРИНДОПРИЛ ЭРБУМИНА
WO2008050185A2 (en) * 2006-10-26 2008-05-02 Glenmark Pharmaceuticals Limited Novel polymorphs of perindopril erbumine
WO2008114270A1 (en) * 2007-03-22 2008-09-25 Aarti Healthcare Limited Process for the preparation of perindopril erbumine salt and novel polymorph (s) thereof
SI22543A (sl) 2007-06-27 2008-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Nove soli perindoprila
PT105315B (pt) 2010-09-29 2013-01-16 Inst Superior Tecnico Uma nova forma cristalina hidratada de erbumina de perindopril, métodos para a sua preparação e sua utilização em preparações farmacêuticas

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508729A (en) * 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
FR2503155A2 (fr) 1980-10-02 1982-10-08 Science Union & Cie Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
FR2620709B1 (fr) * 1987-09-17 1990-09-07 Adir Procede de synthese industrielle du perindopril et de ses principaux intermediaires de synthese
WO1994015957A1 (en) * 1993-01-08 1994-07-21 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Method of crystallizing n2-((s)-1-ethoxycarbonyl-3-phenylpropyl)-n6-trifluoroacetyl-l-lysyl-l-proline
FR2807431B1 (fr) 2000-04-06 2002-07-19 Adir Nouveau procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables
FR2811319B1 (fr) 2000-07-06 2002-08-23 Adir Nouvelle forme cristalline beta du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2811320B1 (fr) 2000-07-06 2002-08-23 Adir Nouvelle forme cristalline alpha du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2811318B1 (fr) * 2000-07-06 2002-08-23 Adir Nouvelle forme cristalline gamma du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2827860B1 (fr) 2001-07-24 2004-12-10 Servier Lab Nouveau procede de synthese de derives de l'acide (2s, 3as, 7as)-1-[(s)-alanyl]-octahydro-1h-indole-2-carboxyline et application a la synthese du perindopril
GB2395195A (en) * 2002-11-18 2004-05-19 Cipla Ltd Preparation of perindopril from carboxy-protected precursor, & perindopril monohydrates for use as angiotensin converting enzyme (ACE) inhibitors
CA2631493A1 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration

Also Published As

Publication number Publication date
PT1636185E (pt) 2012-04-16
KR20060035636A (ko) 2006-04-26
BRPI0411966A (pt) 2006-08-29
US20100160404A1 (en) 2010-06-24
CA2530550C (en) 2017-04-04
NO333128B1 (no) 2013-03-11
ZA200600655B (en) 2007-05-30
EA200501859A1 (ru) 2006-06-30
US7705046B2 (en) 2010-04-27
EP1636185B1 (de) 2012-01-11
EA008603B1 (ru) 2007-06-29
WO2004113293A1 (de) 2004-12-29
HK1093984A1 (en) 2007-03-16
NZ544160A (en) 2008-07-31
JP2007507418A (ja) 2007-03-29
CY1112597T1 (el) 2016-02-10
AU2004249345B8 (en) 2009-06-25
US20070135512A1 (en) 2007-06-14
CA2530550A1 (en) 2004-12-08
MXPA05013811A (es) 2006-06-27
ES2382171T3 (es) 2012-06-06
SI1636185T1 (sl) 2012-06-29
CN100395235C (zh) 2008-06-18
AU2004249345B2 (en) 2009-02-26
ATE540924T1 (de) 2012-01-15
NO20060256L (no) 2006-01-18
PL1636185T3 (pl) 2012-12-31
CN101333181A (zh) 2008-12-31
AU2004249345A1 (en) 2004-12-29
US7981921B2 (en) 2011-07-19
DK1636185T3 (da) 2012-05-07
EP1636185A1 (de) 2006-03-22

Similar Documents

Publication Publication Date Title
JP3592296B2 (ja) ペリンドプリルｔｅｒｔ−ブチルアミン塩の新しいγ結晶形、その製造方法及びこれを含む医薬組成物
US7981921B2 (en) Crystalline forms of perindopril erbumine
JP3602826B2 (ja) ペリンドプリルｔｅｒｔ−ブチルアミン塩のα結晶形
CN1072667C (zh) 含咪唑取代基的巯基烷基肽基化合物及其用作基质金属蛋白酶(mmp)和/或肿瘤坏死因子(tnf)抑制剂
AU2007220435B2 (en) Alpha crystalline form of the arginine salt of perindopril, process for preparing it, and pharmaceutical compositions comprising it
RU2006129346A (ru) Новая кристаллическая форма периндоприла
CN1507437A (zh) 具有5－羟色胺5－ht1a活性的支链金刚烷基及降金刚烷基芳基－与芳烷基－哌嗪
JP4347342B2 (ja) ペリンドプリル及びその薬学的に許容し得る塩の新規合成方法
ZA200300129B (en) Novel form of (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide.
JP4347341B2 (ja) ペリンドプリル及びその薬学的に許容し得る塩の新規合成方法
JP2009505970A (ja) ペリンドプリルエルブミンの新規結晶形
AU2006281684B2 (en) A process for the preparation of perindopril erbumine
US4380644A (en) 2-Oxoimidazolidine derivatives
JP2002504153A (ja) 結晶性ロキシフィバン
JPS584770A (ja) 抗高血圧剤としてのイソキノリンカルボン酸誘導体
CN1606440A (zh) 取代的咪唑烷类化合物,其制备方法,其作为药物或诊断剂的用途以及含有取代的咪唑烷类化合物的药物
CN1290581C (zh) 高血压症治疗药
EP1597230A1 (en) Novel crystalline forms of trandolapril
EA007988B1 (ru) ξ-ЗЕТА ФОРМА ПЕРИНДОПРИЛ ЭРБУМИНА
AU2007203451A1 (en) Pharmaceutical composition containing a crystalline form of perindopril tert-butylamine salt

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1093984

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1093984

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080618

Termination date: 20190618

CF01 Termination of patent right due to non-payment of annual fee